Chemistry:KNX-101
From HandWiki
KNX-101 is a 15-lipoxygenase (15-LOX; ALOX15) inhibitor which is under development for the treatment of chronic agitation and aggression as well as acute and chronic pain.[1][2] Whereas its predecessor KNX-100 (SOC-1) is described as a "short-acting" 15-LOX inhibitor, KNX-101 is said to be a "long-acting" 15-LOX inhibitor.[1][2] Both KNX-100 and KNX-101 produce antiaggressive effects without causing sedation in the chronic social isolation model in rodents, whereas the atypical antipsychotic risperidone only reduces aggression at doses that also induce sedation.[1] KNX-101 is under development by Kinoxis Therapeutics.[1][2] As of January 2026, it is in the preclinical research stage of development.[1][2]
See also
- List of investigational agitation drugs
- List of investigational aggression drugs
- List of investigational analgesics
- KNX-100 (SOC-1)
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "Developing Novel ALOX15 Inhibitors for Dementia and Pain, High-Need CNS Indications". Sachs Associates 9th Annual Neuroscience Innovation Forum for Business Development, Licensing & Investment, 11th January 2026, Marines' Memorial Club, San Francisco, USA. 11 January 2026. https://www.youtube.com/watch?v=bOqOipQDjHg.
- ↑ 2.0 2.1 2.2 2.3 "Pipeline". Kinoxis Therapeutics. 29 May 2026. https://kinoxistherapeutics.com/pipeline/.
External links
 |  |
